Ramez N Eskander

7PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 10, 2026
Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.

|Jan 08, 2026
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.

Jason K Sicklick, Daisuke Nishizaki, Hirotaka Miyashita

|Sep 26, 2025
Ovarian Tumor FAK Inhibition Releases Omega-3 Fatty Acids Stimulating GATA6 Peritoneal Macrophage CXCL13 Production Enhancing Immunotherapy.

Xiao Lei Chen, Kevin M Tharp, Marjaana Ojalill

|Mar 05, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Ramez N Eskander, Michael W Sill, Lindsey Beffa

|Apr 15, 2024
Top advances of the year: Uterine cancer.

Britt K Erickson, Brian Slomovitz, Matthew Powell

|Aug 24, 2023
Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy.

Jessica Jou, Shumei Kato, Hirotaka Miyashita

Pageof 2

Frequent Collaborators

3 joint publications

Shumei Kato

3 joint publications

Razelle Kurzrock

2 joint publications

Jason Sicklick

2 joint publications

Ryosuke Okamura